Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
LION: Lymphadenectomy in ovarian neoplasms – A prospective randomized AGO study group led gynecologic cancer intergroup trial
30 března, 2021 12:58 amMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Abstract number: 5500 Citation: J Clin Oncol 35,...
LION Findings Endorse Omitting Lymphadenectomy in Node-Negative Advanced Ovarian Cancer
30 března, 2021 12:53 amAccording to results of the large randomized LION Gynecologic Cancer Intergroup trial, routine pelvic and para-aortic lymphadenectomy offers no benefit...
NOVINKY Z ASCO – GYNEKOLOGICKÉ MALIGNITY
30 března, 2021 12:43 amTaké na letošním ročníku konference Americké společnosti klinické onkologie (ASCO) byl věnován prostor prezentacím zaměřeným na gynekologické nádory. Zaznělo několik sdělení, která...
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER
30 března, 2021 12:39 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: 501 Citation: J Clin Oncol...
A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03)
30 března, 2021 12:31 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy Abstract number: 507 Citation: J Clin Oncol 35,...
Phase II study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A
30 března, 2021 12:23 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer-Metastatic Abstract number: 1008 Citation: J Clin Oncol 35, 2017...
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
30 března, 2021 12:17 amMeeting: 2017 ASCO Annual Meeting Track: Title:Breast Cancer-Metastatic Abstract number: 1002 Citation: J Clin Oncol 35, 2017...
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
30 března, 2021 12:00 amMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: LBA500 Citation: J Clin Oncol...
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
29 března, 2021 11:04 pmJune 5, 2017 Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to...
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
29 března, 2021 10:59 pmMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Breast Cancer – Metastatic Abstract number: LBA4 Citation:...